It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis. Deleterious variation within components of the transforming growth factor-β pathway, particularly the bone morphogenetic protein type 2 receptor (BMPR2), underlies most heritable forms of PAH. To identify the missing heritability we perform whole-genome sequencing in 1038 PAH index cases and 6385 PAH-negative control subjects. Case-control analyses reveal significant overrepresentation of rare variants in ATP13A3, AQP1 and SOX17, and provide independent validation of a critical role for GDF2 in PAH. We demonstrate familial segregation of mutations in SOX17 and AQP1 with PAH. Mutations in GDF2, encoding a BMPR2 ligand, lead to reduced secretion from transfected cells. In addition, we identify pathogenic mutations in the majority of previously reported PAH genes, and provide evidence for further putative genes. Taken together these findings contribute new insights into the molecular basis of PAH and indicate unexplored pathways for therapeutic intervention.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




















1 Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Department of Haematology, University of Cambridge, Cambridge, United Kingdom; NIHR BioResource—Rare Diseases, Cambridge, United Kingdom
2 Department of Medicine, University of Cambridge, Cambridge, United Kingdom
3 Molecular and Clinical Sciences Research Institute, St George’s, University of London, London, United Kingdom; Division of Genetics & Molecular Medicine, King’s College London, London, United Kingdom
4 Royal Papworth Hospital, Papworth Everard, Cambridge, United Kingdom
5 Institute of Medical and Biomedical Education, St George’s University of London, London, United Kingdom
6 Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Royal Papworth Hospital, Papworth Everard, Cambridge, United Kingdom
7 Department of Haematology, University of Cambridge, Cambridge, United Kingdom; NIHR BioResource—Rare Diseases, Cambridge, United Kingdom
8 Addenbrooke’s Hospital, Cambridge, United Kingdom
9 Cleveland Clinic, Cleveland, Ohio, United States
10 VU University Medical Center, Amsterdam, The Netherlands
11 Golden Jubilee National Hospital, Glasgow, United Kingdom
12 Royal Free Hospital, London, United Kingdom
13 Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom
14 University of Newcastle, Newcastle, United Kingdom
15 Department of Molecular Medicine, University of Pavia, Pavia, Italy; Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
16 Département de génétique, hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, and UMR_S 1166-ICAN, INSERM, UPMC Sorbonne Universités, Paris, France
17 University of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL) and of the Excellence Cluster Cardio-Pulmonary System (ECCCPS), Giessen, Germany
18 Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
19 University of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL) and of the Excellence Cluster Cardio-Pulmonary System (ECCCPS), Giessen, Germany; Imperial College London, London, United Kingdom
20 National Heart & Lung Institute, Imperial College London, London, United Kingdom
21 Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay; AP-HP, Service de Pneumologie, Centre de référence de l’hypertension pulmonaire; INSERM UMR_S 999, Hôpital Bicêtre, Le Kremlin-Bicêtre, Paris, France
22 Imperial College London, London, United Kingdom
23 Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria; Medical University of Graz, Graz, Austria
24 Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom
25 Great Ormond Street Hospital, London, United Kingdom
26 Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria
27 Blizard Institute, Queen Mary University of London, London, United Kingdom
28 Royal Brompton Hospital, London, United Kingdom; Imperial College London, London, United Kingdom
29 Department of Haematology, University of Cambridge, Cambridge, United Kingdom; Wellcome Trust Sanger Institute, Hinxton, United Kingdom
30 Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
31 Division of Genetics & Molecular Medicine, King’s College London, London, United Kingdom
32 Department of Medicine, University of Cambridge, Cambridge, United Kingdom; NIHR BioResource—Rare Diseases, Cambridge, United Kingdom